The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations
Open accessAbstract
Inhaled corticosteroids (ICS) have limited efficacy in reducing chronic obstructive pulmonary disease (COPD) exacerbations and increase pneumonia risk, through unknown mechanisms. Rhinoviruses precipitate most exacerbations and increase susceptibility to secondary bacterial infections. Here, we show that the ICS fluticasone propionate (FP) impairs innate and acquired antiviral immune responses leading to delayed virus clearance and previously unrecognised adverse effects of enhanced mucus, impaired antimicrobial peptide secretion and increased pulmonary bacterial load during virus-induced exacerbations. Exogenous interferon-β reverses these effects. FP suppression of interferon may occur through inhibition of TLR3- and RIG-I virus-sensing pathways. Mice deficient in the type I interferon-α/β receptor (IFNAR1−/−) have suppressed antimicrobial peptide and enhanced mucin responses to rhinovirus infection. This study identifies type I interferon as a central regulator of antibacterial immunity and mucus production. Suppression of interferon by ICS during virus-induced COPD exacerbations likely mediates pneumonia risk and raises suggestion that inhaled interferon-β therapy may protect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Seth, R. B., Sun, L., Ea, C.-K., & Chen, Z. J. (2005) · Cell · doi:10.1016/j.cell.2005.08.012 · Cited by 3,329
Role of deficient type III interferon-λ production in asthma exacerbations
Contoli, M., Message, S. D., Laza-Stanca, V., Edwards, M. R., Wark, P. A. B., Bartlett, N. W., Kebadze, T., Mallia, P., Stanciu, L. A., Parker, H. L., et al. (2006) · Nature Medicine · doi:10.1038/nm1462 · Cited by 1,006
Self-citationIto, K., Yamamura, S., Essilfie-Quaye, S., Cosio, B., Ito, M., Barnes, P. J., & Adcock, I. M. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050466 · Cited by 638
Voynow, J. A., & Rubin, B. K. (2009) · Chest · doi:10.1378/chest.08-0412 · Cited by 504
Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation
Bartlett, N. W., Walton, R. P., Edwards, M. R., Aniscenko, J., Caramori, G., Zhu, J., Glanville, N., Choy, K. J., Jourdan, P., Burnet, J., et al. (2008) · Nature Medicine · doi:10.1038/nm1713 · Cited by 375
Self-citationOral prednisone therapy in experimental rhinovirus infections
Gustafson, L. M., Proud, D., Hendley, J. O., Hayden, F. G., & Gwaltney, J. M. (1996) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(96)80077-7 · Cited by 122
Farr, B. M., Gwaltney, J. M., Hendley, J. O., Hayden, F. G., Naclerio, R. M., McBride, T., Doyle, W. J., Sorrentino, J. V., Riker, D. K., & Proud, D. (1990) · Journal of Infectious Diseases · doi:10.1093/infdis/162.5.1173 · Cited by 109
The common cold: effects of intranasal fluticasone propionate treatment
Puhakka, T., Mäkelä, M. J., Malmström, K., Uhari, M., Savolainen, J., Terho, E. O., Pulkkinen, M., & Ruuskanen, O. (1998) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(98)70301-x · Cited by 89
Number needed to treat in COPD: exacerbations versus pneumonias
Suissa, S. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202709 · Cited by 77
Skevaki, C. L., Christodoulou, I., Spyridaki, I. S., Tiniakou, I., Georgiou, V., Xepapadaki, P., Kafetzis, D. A., & Papadopoulos, N. G. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2009.03307.x · Cited by 67
Cited by
Lambrecht, B. N., Hammad, H., & Fahy, J. V. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.018 · Cited by 1,039
Halpin, D. M. G., Criner, G. J., Papi, A., Singh, D., Anzueto, A., Martinez, F. J., Agusti, A. A., & Vogelmeier, C. F. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202009-3533so · Cited by 760
Functional effects of the microbiota in chronic respiratory disease
Budden, K. F., Shukla, S. D., Rehman, S. F., Bowerman, K. L., Keely, S., Hugenholtz, P., Armstrong-James, D. P. H., Adcock, I. M., Chotirmall, S. H., Chung, K. F., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30510-1 · Cited by 446
Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective
Halpin, D. M. G., Singh, D., & Hadfield, R. M. (2020) · European Respiratory Journal · doi:10.1183/13993003.01009-2020 · Cited by 310
Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?
Ritchie, A. I., & Singanayagam, A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30691-7 · Cited by 283
Self-citation
Metadata
- Authors
- Singanayagam, A., Glanville, N., Girkin, J. L., Ching, Y. M., Marcellini, A., Porter, J. D., Toussaint, M., Walton, R. P., Finney, L. J., Aniscenko, J., Zhu, J., Trujillo-Torralbo, M.-B., Calderazzo, M. A., Grainge, C., Loo, S.-L., Veerati, P. C., Pathinayake, P. S., Nichol, K. S., Reid, A. T., James, P. L., Solari, R., Wark, P. A. B., Knight, D. A., Moffatt, M. F., Cookson, W. O., Edwards, M. R., Mallia, P., Bartlett, N. W., & Johnston, S. L.
- Venue
- Nature Communications
- Published
- 2018-06-08
- Volume
- 9
- Issue
- 1
- Pages
- 2229-2229
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2806885108
- Cited by
- 196
- References
- 10
- FWCI
- 18.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. https://app.cochat.ai/papers/10.1038/s41467-018-04574-1
- The paper
- Singanayagam, A., Glanville, N., Girkin, J. L., Ching, Y. M., Marcellini, A., Porter, J. D., Toussaint, M., Walton, R. P., Finney, L. J., Aniscenko, J., Zhu, J., Trujillo-Torralbo, M.-B., Calderazzo, M. A., Grainge, C., Loo, S.-L., Veerati, P. C., Pathinayake, P. S., Nichol, K. S., Reid, A. T., . . . Johnston, S. L. (2018). Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. Nature Communications. https://doi.org/10.1038/s41467-018-04574-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.